Comparison of Hospitalization and Death Frequencies in Influenza Outpatients Treated with Baloxavir marboxil or Neuraminidase Inhibitors： an Observational Database Study

laninamivir（0.91％（234／25,831）). Age-adjusted OR（vs baloxavir, as denomi-nator）and 95％ CIs was 1.125［0.961-1.317], 1.173［0.726-1.897］and 0.944［0.783-1.140］for oseltamivir, zanamivir and laninamivir, respectively. In addition, the proportion of death in patients with baloxavir （0.03％, n＝5）was comparable with that in oseltamivir（0.03％, n＝16), laninamivir（0.01％, n＝3), while there were no deaths in zanamivir due to the small number of patients. Conclusion ：In an observational study of Japanese acute hospital-based claims database, the frequency of severe events in influenza outpatients was comparable with that in other treatment groups, supporting that baloxavir may help prevent severe influenza as a new treatment option.